

Aksam Yassin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11821952/aksam-yassin-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14 papers	826 citations	12 h-index	14 g-index
14 ext. papers	889 ext. citations	2 avg, IF	3.62 L-index

#	Paper	IF	Citations
14	Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data. <i>Vascular Health and Risk Management</i> , 2021 , 17, 497-508	4.4	1
13	Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. <i>Aging Male</i> , 2017 , 20, 45-48	2.1	24
12	Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. <i>Aging Male</i> , 2017 , 20, 125-133	2.1	27
11	Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. <i>Aging Male</i> , 2016 , 19, 64-9	2.1	80
10	Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. <i>Clinical Endocrinology</i> , 2016 , 84, 107-14	3.4	35
9	Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. <i>Journal of Urology</i> , 2015 , 193, 80-6	2.5	65
8	Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). <i>Journal of Sexual Medicine</i> , 2011 , 8, 284-93	1.1	111
7	Endocrine aspects of male sexual dysfunctions. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1627-56	1.1	142
6	A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. <i>Journal of Andrology</i> , 2008 , 29, 102-5		107
5	An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. <i>Archives of Andrology</i> , 2007 , 53, 353-7		61
4	More than eight yearsfhands-on experience with the novel long-acting parenteral testosterone undecanoate. <i>Asian Journal of Andrology</i> , 2007 , 9, 291-7	2.8	48
3	Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2006 , 3, 883-891	1.1	56
2	Intramuscular testosterone undecanoate for the treatment of male hypogonadismReview of recent data. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006 , 3, 356-362		2
1	Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. <i>Journal of Sexual Medicine</i> , 2005 , 2, 856-64	1.1	67